Japanese encephalitis vaccine, inactivated, adsorbed - Biologic Drug Details

Summary for japanese encephalitis vaccine, inactivated, adsorbed

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for japanese encephalitis vaccine, inactivated, adsorbed

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Japanese Encephalitis Virus Vaccine
Chemical Structure	Japanese Encephalitis Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for japanese encephalitis vaccine, inactivated, adsorbed Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for japanese encephalitis vaccine, inactivated, adsorbed Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for japanese encephalitis vaccine, inactivated, adsorbed Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Japanese Encephalitis Vaccine

Introduction

Japanese Encephalitis (JE) is a severe mosquito-borne flavivirus disease prevalent in many parts of Asia and other regions. The market for the Japanese Encephalitis vaccine is driven by several key factors, including increasing disease incidence, government initiatives, and advancements in vaccine technology.

Market Growth Drivers

Increasing Incidence of Japanese Encephalitis

The global JE vaccine market is expected to grow significantly due to the rising incidence of the disease. According to the World Health Organization (WHO), approximately 68,000 clinical cases of JE are reported worldwide each year, driving the demand for vaccines[4].

Government Initiatives and National Immunization Programs

Governments across various nations, particularly in high-risk regions like China and India, are including JE vaccination in their national immunization programs. This inclusion is a major growth driver for the industry, as it ensures widespread vaccination and reduces the incidence of the disease[1][4].

Rising Health Awareness and Routine Immunization

The growing trend of routine immunization and increasing health awareness among the population are contributing to the strong demand for JE vaccines. This trend is particularly pronounced in developing regions where the risk of JE is higher[1].

Investments in R&D

Significant investments in research and development (R&D) are aiding the growth of the JE vaccine market. These investments lead to the development of more effective and safer vaccines, such as the inactivated, adsorbed IXIARO vaccine, which has shown high levels of seroprotection against JE virus[1][3].

Market Trends

Growing R&D Activities

The market is witnessing an increase in R&D activities aimed at improving vaccine efficacy and safety. For example, the IXIARO vaccine has demonstrated long-term seroprotection and a favorable safety profile, making it a promising option for preventive vaccination[3].

Initiation of National Immunization Programs

The initiation of national immunization programs by governments is a key trend driving market growth. These programs ensure that a large population is vaccinated, reducing the overall incidence of the disease and driving demand for vaccines[1][4].

Technological Advancements

Technological advancements in vaccine production, such as the use of cultured Vero cells for manufacturing inactivated vaccines, are enhancing the market. These advancements improve the immunogenicity and efficacy of the vaccines, making them more attractive to both consumers and healthcare providers[3].

Regional Market Analysis

Asia Pacific

The Asia Pacific region, particularly China and India, is at high risk for Japanese encephalitis. As a result, these countries are conducting mass vaccinations, which significantly boosts the demand for JE vaccines in this region[1].

Other Regions

Other regions, including North America, Latin America, the Middle East and Africa, and Europe, also contribute to the market, although the demand is generally lower compared to the Asia Pacific region. However, these regions still play a crucial role in the global market dynamics[1].

Types of Vaccines

Inactivated, Recombinant, and Live Attenuated Vaccines

The market includes various types of JE vaccines, such as inactivated, recombinant, and live attenuated vaccines. The inactivated, adsorbed IXIARO vaccine is a notable example, offering high levels of seroprotection and a favorable safety profile[1][3].

Distribution Channels

Hospitals, Retail, and Online

The leading distribution channels for JE vaccines include hospitals, retail pharmacies, and online platforms. The rise in the number of retail pharmacies and their ease of access are creating opportunities for market growth[1].

Key Players

The market is dominated by several key players, including Valneva SE, Sanofi, Bharat Biotech International Limited, and Chengdu Institute of Biological Products Co. Ltd. These companies are involved in various activities such as capacity expansions, plant turnarounds, and mergers and acquisitions, which influence market dynamics[1].

Financial Trajectory

Market Size and Growth Rate

The global JE vaccine market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period of 2024-2032. This growth is driven by the increasing incidence of the disease, government initiatives, and technological advancements[1].

Cost-Effectiveness Analysis

The cost-effectiveness of JE vaccination varies significantly depending on the risk group and disease incidence. For example, the cost to prevent one JE case can range from approximately $0.6 billion to $7.9 billion depending on the risk group, highlighting the economic impact of vaccination strategies[2].

Revenue and Investment

The market is expected to generate significant revenue, driven by the growing demand for vaccines. Investments in R&D and the expansion of production capacities by key players are also contributing to the financial growth of the market[1].

Challenges and Restraints

Lack of Awareness

One of the major challenges facing the market is the lack of awareness about the disease, particularly in rural and underdeveloped areas. This lack of awareness can hamper the growth of the market by reducing vaccination rates[1][4].

Key Takeaways

• The global JE vaccine market is driven by increasing disease incidence, government initiatives, and technological advancements.
• The Asia Pacific region, particularly China and India, is a significant market due to high disease incidence.
• Key players are investing heavily in R&D and expanding production capacities.
• The market is expected to grow at a CAGR of 5.5% during the forecast period.
• Lack of awareness is a major challenge that needs to be addressed.

Frequently Asked Questions (FAQs)

Q: What is the expected growth rate of the global Japanese Encephalitis vaccine market? A: The global JE vaccine market is expected to grow at a CAGR of 5.5% during the forecast period of 2024-2032[1].

Q: Which regions are at high risk for Japanese Encephalitis? A: The Asia Pacific region, particularly China and India, is at high risk for Japanese Encephalitis[1].

Q: What types of Japanese Encephalitis vaccines are available? A: The market includes inactivated, recombinant, and live attenuated vaccines[1].

Q: Who are the major players in the Japanese Encephalitis vaccine market? A: Major players include Valneva SE, Sanofi, Bharat Biotech International Limited, and Chengdu Institute of Biological Products Co. Ltd.[1].

Q: What is the impact of government initiatives on the Japanese Encephalitis vaccine market? A: Government initiatives, such as including JE vaccination in national immunization programs, are significant growth drivers for the market[1][4].

Citations

1. Expert Market Research: Japanese Encephalitis (JE) Vaccine Market Size 2024-2032
2. CDC: Japanese Encephalitis Vaccine Evidence to Recommendations
3. PubMed: Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]
4. Data Bridge Market Research: Global Japanese Encephalitis Market Share, Future Analysis And Industry
5. PATH: sa 14-14-2 live japanese encephalitis (je) vaccine - PATH